Drugs, Germs, and Joints: Antibiotics, Gut Microbiota, and Juvenile Idiopathic Arthritis

药物、细菌和关节:抗生素、肠道微生物群和幼年特发性关节炎

基本信息

项目摘要

Project Summary Little is known about why children develop juvenile idiopathic arthritis (JIA). Research implicates microbiome imbalance (dysbiosis) of the mouth and gut in the development and activity of rheumatoid arthritis, a disease distinct from most forms of JIA. Gut dysbiosis may also mediate eye inflammation (uveitis), a common, vision-threatening complication of JIA. Some children with a less common form of JIA have evidence of dysbiosis, and antibiotics (major microbiome disrupters) are associated with new-onset JIA in large populations. The overall goal of this research is to understand the mechanisms underlying the development and course of JIA in order to develop new ways of preventing and treating this family of chronic diseases. The main objective of this study is to examine the complex relationship between antibiotics, infections, and dysbiosis in relation to JIA pathogenesis and activity. This project will focus on the most common form of JIA, oligoarticular JIA, which is associated with high rates of uveitis. The first aim will examine whether gut microbiota from children with incident oligoarticular JIA exhibit dysbiosis (primary exposure) compared with gut microbiota of matched unaffected children in a multicenter case-control study of prospectively recruited children. The second aim will prospectively follow those children with oligoarticular JIA to determine whether gut dysbiosis A) resolves with inactive disease (in a self-controlled study comparing microbiota at diagnosis and at the time of inactive disease) and/or B) increases with JIA flare (in a case-control study comparing microbiota at flare and at the time of inactive disease). Both aims will use self-collected stool samples along with clinical data, including antibiotic use (secondary exposure). Dysbiosis will be defined as having decreased gut microbial diversity and distinct overall microbial composition relative to the comparator group. The analysis will also explore differences in the relative abundance of specific species between groups as well as associations between dysbiosis and clinical features of JIA (e.g., uveitis). The third aim will test whether antibiotic use in children with JIA, particularly drugs with antianaerobic coverage, is associated with new antirheumatic drug use within 3 months as a proxy for increased JIA disease activity. This aim will use administrative claims data and a self-controlled case series design. The proposed K23 project will provide this pediatric rheumatologist with an integrated plan of mentored patient-oriented research, career development activities, and formal training in bioinformatics. Guided by expert mentors and talented collaborators, the research and training activities outlined in this application will enable the principal investigator to mature from an observational epidemiologist into an independent patient- oriented and translational researcher. These opportunities will equip this investigator with a much larger set of skills to answer important and novel questions about pediatric rheumatic diseases.
项目摘要 关于儿童患幼年特发性关节炎(JIA)的原因知之甚少。研究表明, 在类风湿性关节炎的发展和活动中口腔和肠道的微生物组不平衡(生态失调), 一种与大多数JIA不同的疾病。肠道生态失调也可能介导眼部炎症(葡萄膜炎), JIA常见的威胁视力的并发症。一些患有不太常见的JIA的儿童有证据表明, 和抗生素(主要的微生物组干扰物)与新发JIA大 人口。这项研究的总体目标是了解发展的机制, 和病程,以期为这一家族慢性病的防治开辟新的途径。的 本研究的主要目的是研究抗生素、感染和 生态失调与JIA发病机制和活动有关。本项目将重点关注JIA最常见的形式, 少关节型JIA与葡萄膜炎的高发病率相关。 第一个目标是研究来自少关节JIA患儿的肠道微生物群是否表现出 在一项多中心研究中,与匹配的未受影响儿童的肠道微生物群相比, 前瞻性招募儿童的病例对照研究。第二个目标将前瞻性地跟踪这些儿童 用少关节JIA来确定肠道生态失调A)是否随着非活动性疾病而消退(在一个自我对照的研究中, 一项比较诊断时和非活动性疾病时微生物群)和/或B)随JIA发作而增加的研究 (in一项病例对照研究,比较爆发时和非活动性疾病时的微生物群)。这两个目标将使用 自我采集的粪便样本沿着临床数据,包括抗生素使用(二次暴露)。生态失调 将被定义为具有减少的肠道微生物多样性和不同的总体微生物组成, 对照组。分析还将探讨特定物种相对丰度的差异 组之间以及JIA的生态失调和临床特征之间的关联(例如,葡萄膜炎)。第三 目的将测试JIA儿童使用抗生素,特别是抗厌氧药物, 与3个月内使用新的抗风湿药物相关,作为JIA疾病活动性增加的代表。这 aim将使用行政索赔数据和自我对照病例系列设计。 拟议的K23项目将为这位儿科风湿病学家提供一个综合计划, 以病人为导向的研究,职业发展活动,以及生物信息学的正规培训。指导 专家导师和有才华的合作者,本申请中概述的研究和培训活动将 使主要研究者从观察性流行病学家成长为独立的患者- 导向和翻译研究。这些机会将使这位调查员拥有更大的一套 技能,以回答有关小儿风湿性疾病的重要和新颖的问题。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Daniel Benjamin Horton其他文献

Daniel Benjamin Horton的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Daniel Benjamin Horton', 18)}}的其他基金

Safety of Drugs Commonly Used Off-Label in Children Despite Insufficient Evidence of Efficacy and Safety
尽管有效性和安全性证据不足,但儿童常用超说明书药物的安全性
  • 批准号:
    10707404
  • 财政年份:
    2022
  • 资助金额:
    $ 18.99万
  • 项目类别:
Safety of Drugs Commonly Used Off-Label in Children Despite Insufficient Evidence of Efficacy and Safety
尽管有效性和安全性证据不足,但儿童常用超说明书药物的安全性
  • 批准号:
    10503951
  • 财政年份:
    2022
  • 资助金额:
    $ 18.99万
  • 项目类别:
Antibiotics, Juvenile Idiopathic Arthritis, and Antirheumatic Treatment Response
抗生素、幼年特发性关节炎和抗风湿治疗反应
  • 批准号:
    10199933
  • 财政年份:
    2019
  • 资助金额:
    $ 18.99万
  • 项目类别:
Antibiotics, Juvenile Idiopathic Arthritis, and Antirheumatic Treatment Response
抗生素、幼年特发性关节炎和抗风湿治疗反应
  • 批准号:
    10442518
  • 财政年份:
    2019
  • 资助金额:
    $ 18.99万
  • 项目类别:
Drugs, Germs, and Joints: Antibiotics, Gut Microbiota, and Juvenile Idiopathic Arthritis
药物、细菌和关节:抗生素、肠道微生物群和幼年特发性关节炎
  • 批准号:
    9353294
  • 财政年份:
    2016
  • 资助金额:
    $ 18.99万
  • 项目类别:
Glucocorticoid use and osteonecrosis in chronic pediatric inflammatory diseases
糖皮质激素在儿科慢性炎症性疾病中的使用和骨坏死
  • 批准号:
    8784410
  • 财政年份:
    2014
  • 资助金额:
    $ 18.99万
  • 项目类别:

相似国自然基金

靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
  • 批准年份:
    2024
  • 资助金额:
    0 万元
  • 项目类别:
    面上项目
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
  • 批准号:
    2023JJ50274
  • 批准年份:
    2023
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    33 万元
  • 项目类别:
    地区科学基金项目
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
  • 批准号:
    81973577
  • 批准年份:
    2019
  • 资助金额:
    55.0 万元
  • 项目类别:
    面上项目
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
  • 批准号:
    81602908
  • 批准年份:
    2016
  • 资助金额:
    18.0 万元
  • 项目类别:
    青年科学基金项目
高血糖激活滑膜AGE-RAGE-PKC轴致骨关节炎易感的机制研究
  • 批准号:
    81501928
  • 批准年份:
    2015
  • 资助金额:
    18.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
  • 批准号:
    2341426
  • 财政年份:
    2024
  • 资助金额:
    $ 18.99万
  • 项目类别:
    Continuing Grant
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
  • 批准号:
    2341424
  • 财政年份:
    2024
  • 资助金额:
    $ 18.99万
  • 项目类别:
    Continuing Grant
PROTEMO: Emotional Dynamics Of Protective Policies In An Age Of Insecurity
PROTEMO:不安全时代保护政​​策的情绪动态
  • 批准号:
    10108433
  • 财政年份:
    2024
  • 资助金额:
    $ 18.99万
  • 项目类别:
    EU-Funded
The role of dietary and blood proteins in the prevention and development of major age-related diseases
膳食和血液蛋白在预防和发展主要与年龄相关的疾病中的作用
  • 批准号:
    MR/X032809/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.99万
  • 项目类别:
    Fellowship
Atomic Anxiety in the New Nuclear Age: How Can Arms Control and Disarmament Reduce the Risk of Nuclear War?
新核时代的原子焦虑:军控与裁军如何降低核战争风险?
  • 批准号:
    MR/X034690/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.99万
  • 项目类别:
    Fellowship
Walkability and health-related quality of life in Age-Friendly Cities (AFCs) across Japan and the Asia-Pacific
日本和亚太地区老年友好城市 (AFC) 的步行适宜性和与健康相关的生活质量
  • 批准号:
    24K13490
  • 财政年份:
    2024
  • 资助金额:
    $ 18.99万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Discovering the (R)Evolution of EurAsian Steppe Metallurgy: Social and environmental impact of the Bronze Age steppes metal-driven economy
发现欧亚草原冶金的(R)演变:青铜时代草原金属驱动型经济的社会和环境影响
  • 批准号:
    EP/Z00022X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.99万
  • 项目类别:
    Research Grant
ICF: Neutrophils and cellular senescence: A vicious circle promoting age-related disease.
ICF:中性粒细胞和细胞衰老:促进与年龄相关疾病的恶性循环。
  • 批准号:
    MR/Y003365/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.99万
  • 项目类别:
    Research Grant
Doctoral Dissertation Research: Effects of age of acquisition in emerging sign languages
博士论文研究:新兴手语习得年龄的影响
  • 批准号:
    2335955
  • 财政年份:
    2024
  • 资助金额:
    $ 18.99万
  • 项目类别:
    Standard Grant
Shaping Competition in the Digital Age (SCiDA) - Principles, tools and institutions of digital regulation in the UK, Germany and the EU
塑造数字时代的竞争 (SCiDA) - 英国、德国和欧盟的数字监管原则、工具和机构
  • 批准号:
    AH/Y007549/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.99万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了